CR20200013A - Molécula de polipéptido con especificidad dual mejorada - Google Patents

Molécula de polipéptido con especificidad dual mejorada

Info

Publication number
CR20200013A
CR20200013A CR20200013A CR20200013A CR20200013A CR 20200013 A CR20200013 A CR 20200013A CR 20200013 A CR20200013 A CR 20200013A CR 20200013 A CR20200013 A CR 20200013A CR 20200013 A CR20200013 A CR 20200013A
Authority
CR
Costa Rica
Prior art keywords
polypeptide molecule
dual specificity
enhanced dual
region derived
binding region
Prior art date
Application number
CR20200013A
Other languages
English (en)
Inventor
Sebastian Bunk
Martin Hofmann
Dominik Maurer
Felix Unverdorben
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102017115966.5A external-priority patent/DE102017115966A1/de
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of CR20200013A publication Critical patent/CR20200013A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una molécula de polipéptido biespecífica que comprende una primera cadena polipeptídica y una segunda cadena polipeptídica que proporciona una región de unión derivada de un receptor de linfocito T (TCR) que es específica para un epítopo peptídico asociado al complejo principal de histocompatibilidad (MHC), y una región de unión derivada de un anticuerpo capaz de reclutar células efectoras inmunitarias humanas mediante la unión específica a un antígeno de superficie de dichas células, así como métodos para fabricar la molécula de polipéptido biespecífica, y usos de la misma
CR20200013A 2017-07-14 2018-07-13 Molécula de polipéptido con especificidad dual mejorada CR20200013A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762532713P 2017-07-14 2017-07-14
DE102017115966.5A DE102017115966A1 (de) 2017-07-14 2017-07-14 Polypeptidmolekül mit verbesserter zweifacher Spezifität
DE102017119866 2017-08-30
US201862658318P 2018-04-16 2018-04-16
DE102018108995 2018-04-16
PCT/EP2018/069151 WO2019012138A1 (en) 2017-07-14 2018-07-13 POLYPEPTIDE MOLECULE WITH IMPROVED DOUBLE-SPECIFICITY

Publications (1)

Publication Number Publication Date
CR20200013A true CR20200013A (es) 2020-03-11

Family

ID=62951983

Family Applications (2)

Application Number Title Priority Date Filing Date
CR20200013A CR20200013A (es) 2017-07-14 2018-07-13 Molécula de polipéptido con especificidad dual mejorada
CR20200014A CR20200014A (es) 2017-07-14 2018-07-13 Molécula de polipéptido con especificidad dual mejorada

Family Applications After (1)

Application Number Title Priority Date Filing Date
CR20200014A CR20200014A (es) 2017-07-14 2018-07-13 Molécula de polipéptido con especificidad dual mejorada

Country Status (28)

Country Link
US (7) US20190016802A1 (es)
EP (3) EP3985029A1 (es)
JP (4) JP2020530762A (es)
KR (2) KR20200026994A (es)
CN (2) CN110914308A (es)
AU (2) AU2018298884A1 (es)
BR (2) BR112020000762A2 (es)
CA (2) CA3069610A1 (es)
CO (2) CO2020001029A2 (es)
CR (2) CR20200013A (es)
CY (2) CY1124091T1 (es)
DK (2) DK3428194T3 (es)
ES (2) ES2871146T3 (es)
HR (1) HRP20211744T1 (es)
HU (2) HUE057110T2 (es)
LT (2) LT3428194T (es)
MA (1) MA46299B1 (es)
MD (2) MD3428194T2 (es)
MX (1) MX2020011744A (es)
PE (2) PE20200614A1 (es)
PL (2) PL3652215T3 (es)
PT (2) PT3652215T (es)
RS (2) RS62544B1 (es)
SG (2) SG11202000025SA (es)
SI (2) SI3652215T1 (es)
TW (2) TWI817302B (es)
WO (2) WO2019012138A1 (es)
ZA (1) ZA202000842B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3428194T3 (da) 2017-07-14 2021-11-15 Immatics Biotechnologies Gmbh Forbedret polypeptidmolekyle med dobbelt specificitet
CN112424230A (zh) 2018-05-14 2021-02-26 英美偌科有限公司 双功能结合多肽
GB201904328D0 (en) 2019-03-28 2019-05-15 Immunocore Ltd Specific binding molecules
AU2020283500A1 (en) 2019-05-27 2022-01-27 Immatics US, Inc. Viral vectors and their use in adoptive cellular therapy
DE102019121007A1 (de) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
US20210032370A1 (en) * 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
GB201915282D0 (en) 2019-10-22 2019-12-04 Immunocore Ltd Specific binding molecules
WO2021113748A1 (en) * 2019-12-05 2021-06-10 Arbele Corp. Composition of triaxial antibodies and method of making and using thereof
AU2021225817A1 (en) 2020-02-24 2022-10-20 Immatics US, Inc. Methods for expanding T cells for the treatment of cancer and related malignancies
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
GB202006629D0 (en) 2020-05-05 2020-06-17 Immunocore Ltd Specific binding molecules
GB202010329D0 (en) 2020-07-06 2020-08-19 Immunocore Ltd Specific binding molecules
WO2022040631A1 (en) 2020-08-21 2022-02-24 Immatics US, Inc. Methods for isolating cd8+ selected t cells
JP2024502034A (ja) 2020-12-31 2024-01-17 イマティクス ユーエス，アイエヌシー． Ｃｄ８ポリペプチド、組成物、及びそれらの使用方法
WO2022184805A1 (en) 2021-03-03 2022-09-09 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding sars-cov-2 antigenic peptides in complex with a major histocompatibility complex protein
EP4334361A1 (en) 2021-05-05 2024-03-13 Immatics Biotechnologies GmbH Antigen binding proteins specifically binding prame
US20230024554A1 (en) 2021-06-28 2023-01-26 Immatics Biotechnologies Gmbh Method of characterizing the binding characteristics between a peptide of interest and mhc molecules
EP4113120A1 (en) 2021-06-28 2023-01-04 Immatics Biotechnologies GmbH Method of characterizing the binding characteristics between a peptide of interest and mhc molecules
CN117964777A (zh) * 2021-08-26 2024-05-03 瑅安生物医药（杭州）有限公司 一种接近天然分子的多肽融合分子
US20230089392A1 (en) 2021-09-20 2023-03-23 Immatics US, Inc. Monocyte depletion of t cells populations for t-cell therapy
US20230190807A1 (en) 2021-10-06 2023-06-22 Immatics Biotechnologies Gmbh Tcr compounds, compositions, and methods of treating
US20230192886A1 (en) 2021-11-08 2023-06-22 Immatics Biotechnologies Gmbh Adoptive cell therapy combination treatment and compositions thereof
WO2023081461A1 (en) 2021-11-08 2023-05-11 Immatics US, Inc. Methods for generating cell spheroids
CA3240046A1 (en) * 2021-12-14 2023-06-22 Cdr-Life Ag Dual mhc-targeting t cell engager
WO2023156663A1 (en) 2022-02-20 2023-08-24 Immunocore Limited Hiv-specific binding molecules and tcr
WO2023212697A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
WO2023212691A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. DOMINANT NEGATIVE TGFβ RECEPTOR POLYPEPTIDES, CD8 POLYPEPTIDES, CELLS, COMPOSITIONS, AND METHODS OF USING THEREOF
WO2023212655A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof
WO2023209124A1 (en) 2022-04-29 2023-11-02 Immatics Biotechnologies Gmbh Mammalian display platform for multispecific antigen binding proteins
US20230355678A1 (en) 2022-05-05 2023-11-09 Immatics US, Inc. Methods for improving t cell efficacy
WO2023240124A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells
WO2024033332A1 (en) 2022-08-08 2024-02-15 Immatics Biotechnologies Gmbh Guided positional scanning method
WO2024130179A1 (en) 2022-12-16 2024-06-20 Repertoire Immune Medicines, Inc. T cell receptors binding hpv-16 epitopes

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2018248A1 (en) 1989-06-07 1990-12-07 Clyde W. Shearman Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US8211422B2 (en) 1992-03-18 2012-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric receptor genes and cells transformed therewith
DK0744958T3 (da) 1994-01-31 2003-10-20 Univ Boston Polyklonale antistofbiblioteker
ATE299938T1 (de) 1997-05-02 2005-08-15 Genentech Inc Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
AU2001270609A1 (en) 2000-06-30 2002-01-14 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Heterodimeric fusion proteins
ATE434040T1 (de) 2001-10-01 2009-07-15 Dyax Corp Mehrkettige eukaryontische display-vektoren und deren verwendungen
AU2003271904B2 (en) 2002-10-09 2009-03-05 Adaptimmune Limited Single chain recombinant T cell receptors
LT2275441T (lt) 2005-04-01 2016-12-12 Immunocore Ltd. Dideliu afiniškumu pasižymintys živ t ląstelių receptoriai
ES2707152T3 (es) 2005-04-15 2019-04-02 Macrogenics Inc Diacuerpos covalentes y usos de los mismos
US9284375B2 (en) * 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
CA2609142C (en) 2005-05-27 2016-02-09 Fondazione Centro San Raffaele Del Monte Tabor Therapeutic gene vectors comprising mirna target sequences
AT503861B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von t-zell-rezeptoren
WO2008045437A2 (en) 2006-10-09 2008-04-17 The General Hospital Corporation Chimeric t-cell receptors and t-cells targeting egfrviii on tumors
WO2008145139A1 (en) 2007-05-31 2008-12-04 Genmab A/S Fusion or linked proteins with extended half life
US20100317546A1 (en) 2008-01-11 2010-12-16 Morphosys Ag Display Vectors and Methods and Uses Thereof
EP2258719A1 (en) 2009-05-19 2010-12-08 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Multiple target T cell receptor
WO2011041093A1 (en) 2009-10-01 2011-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
US10464987B2 (en) 2009-10-06 2019-11-05 Abbvie Inc. Human single-chain T cell receptors
US20130129723A1 (en) 2009-12-29 2013-05-23 Emergent Product Development Seattle, Llc Heterodimer Binding Proteins and Uses Thereof
US20130089554A1 (en) 2009-12-29 2013-04-11 Emergent Product Development Seattle, Llc RON Binding Constructs and Methods of Use Thereof
WO2011085178A1 (en) 2010-01-11 2011-07-14 Trustees Of Dartmouth College Monomeric bi-specific fusion protein
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
JP6278598B2 (ja) 2010-11-30 2018-02-14 中外製薬株式会社 細胞傷害誘導治療剤
KR101944557B1 (ko) 2011-02-11 2019-01-30 메모리얼 슬로안 케터링 캔서 센터 에이치엘에이 제한된, 펩타이드­특이성 항원 결합 단백질
US20130078250A1 (en) * 2011-08-23 2013-03-28 Oliver Ast Bispecific t cell activating antigen binding molecules
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
CA2887486A1 (en) 2012-11-30 2014-06-05 Roche Glycart Ag Removal of cancer cells by circulating virus-specific cytotoxic t-cells using cancer cell targeted mhc class i comprising multi-function proteins
NZ708182A (en) 2013-02-26 2019-08-30 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
CN104936985A (zh) 2013-02-26 2015-09-23 罗切格利卡特公司 双特异性t细胞活化性抗原结合分子
RU2020115527A (ru) * 2013-03-14 2020-07-07 Макродженикс, Инк. Биспецифичные молекулы, иммунореактивные с иммунными эффекторными клетками, экспрессирующими активирующий рецептор
AU2014357292B2 (en) 2013-11-27 2020-06-25 Zymeworks Bc Inc. Bispecific antigen-binding constructs targeting HER2
PT3083689T (pt) 2013-12-17 2020-08-27 Genentech Inc Anticorpos anti-cd3 e métodos de utilização
DK3488862T3 (da) 2014-03-25 2022-08-01 Boehringer Ingelheim Animal Health Usa Inc Immunologiske sammensætninger indeholdende svækket histophilus somni
AU2015292590B2 (en) 2014-07-24 2020-01-16 2Seventy Bio, Inc. BCMA chimeric antigen receptors
CA2958200A1 (en) 2014-08-14 2016-02-18 Novartis Ag Treatment of cancer using a gfr alpha-4 chimeric antigen receptor
EP2985294A1 (en) 2014-08-14 2016-02-17 Deutsches Krebsforschungszentrum Recombinant antibody molecule and its use for target cell restricted T cell activation
BR112017007086A2 (pt) * 2014-11-20 2018-01-16 Hoffmann La Roche moléculas de ligação, anticorpo biespecífico, variante de afinidade de uma molécula de ligação, polipeptídeos isolados, polinucleotídeos isolados, vetor, célula hospedeira, método para produzir a molécula de ligação, composição farmacêutica, uso da molécula de ligação, métodos de tratamento de uma doença e para induzir a lise de uma célula
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
GB201423361D0 (en) 2014-12-30 2015-02-11 Immatics Biotechnologies Gmbh Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
GB201504502D0 (en) 2015-03-17 2015-04-29 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
US10744157B2 (en) 2015-03-26 2020-08-18 The Trustees Of Dartmouth College Anti-MICA antigen binding fragments, fusion molecules, cells which express and methods of using
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
GB201505585D0 (en) 2015-03-31 2015-05-13 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
GB201507030D0 (en) 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
GB201507719D0 (en) 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
CA2986254A1 (en) 2015-05-18 2016-11-24 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
EP3095792A1 (en) * 2015-05-19 2016-11-23 Klinikum rechts der Isar der Technischen Universität München T cell receptor with specificity for myeloperoxidase peptide and uses thereof
GB201510771D0 (en) 2015-06-19 2015-08-05 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer
GB201511191D0 (en) 2015-06-25 2015-08-12 Immatics Biotechnologies Gmbh T-cell epitopes for the immunotherapy of myeloma
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
GB201511792D0 (en) 2015-07-06 2015-08-19 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers
GB201512369D0 (en) 2015-07-15 2015-08-19 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
US10159726B2 (en) 2015-08-28 2018-12-25 Immatics Biotechnologies Gmbh Peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
GB201515321D0 (en) 2015-08-28 2015-10-14 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
GB201517538D0 (en) 2015-10-05 2015-11-18 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
WO2017059900A1 (en) 2015-10-07 2017-04-13 Biontech Cell & Gene Therapies Gmbh Antigen receptors and uses thereof
WO2017060201A1 (en) 2015-10-09 2017-04-13 Immatics Biotechnologies Gmbh Anti-wt1/hla-specific antibodies
IL295398A (en) 2015-10-23 2022-10-01 Eureka Therapeutics Inc Antibody/t-cell receptor chimera structures and their uses
GB201521746D0 (en) 2015-12-10 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
GB201521894D0 (en) 2015-12-11 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers
GB201522667D0 (en) 2015-12-22 2016-02-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
GB201522592D0 (en) * 2015-12-22 2016-02-03 Immunocore Ltd T cell receptors
GB201602918D0 (en) 2016-02-19 2016-04-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
GB201603568D0 (en) 2016-03-01 2016-04-13 Immatics Biotechnologies Gmbh Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer
GB201603987D0 (en) 2016-03-08 2016-04-20 Immatics Biotechnologies Gmbh Uterine cancer treatments
US11034767B2 (en) 2016-04-15 2021-06-15 Trustees Of Dartmouth College High affinity B7-H6 antibodies and antibody fragments
EP3472208B9 (en) 2016-06-17 2023-10-04 Medigene Immunotherapies GmbH T cell receptors and uses thereof
CN109643503A (zh) 2016-06-27 2019-04-16 宝洁公司 由口腔护理产品评估牙齿过敏处理的设备和方法
CA3032498A1 (en) 2016-08-02 2018-02-08 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
EP3494984A4 (en) 2016-08-05 2020-07-22 Tohoku University TREATMENT AND DIAGNOSIS OF CANCER OR INFECTIOUS DISEASES USING THE DETECTOR MECHANISM OF A T-CELL RECEPTOR
EP3512875A2 (en) 2016-09-15 2019-07-24 Quadrucept Bio Limited Multimers, tetramers&octamers
CN106831996B (zh) * 2017-03-31 2020-05-19 北京智仁美博生物科技有限公司 具有cd3e和/或her2靶向功能的双特异性抗体及其用途
EP3630811A1 (en) 2017-06-01 2020-04-08 Universität Stuttgart Heterodimerizing ig domains
DK3428194T3 (da) * 2017-07-14 2021-11-15 Immatics Biotechnologies Gmbh Forbedret polypeptidmolekyle med dobbelt specificitet
EP3680338A4 (en) 2017-09-08 2021-06-02 Carsgen Therapeutics Co., Ltd. GENETICALLY MODIFIED LYMPHOCYTE T AND ITS APPLICATION
JPWO2019151392A1 (ja) 2018-01-31 2021-02-04 国立大学法人東北大学 抗原特異的ｍｈｃ発現調節法
CN112424230A (zh) 2018-05-14 2021-02-26 英美偌科有限公司 双功能结合多肽
EA202091977A1 (ru) 2018-05-28 2021-02-09 Драгонфлай Терапьютикс, Инк. Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения
WO2020018715A1 (en) 2018-07-17 2020-01-23 Massachusetts Institute Of Technology Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof
WO2020057610A1 (en) 2018-09-20 2020-03-26 Wuxi Biologics (Shanghai) Co., Ltd. Novel bispecific anti-ctla-4/pd-1 polypeptide complexes
GB201903767D0 (en) 2019-03-19 2019-05-01 Quadrucept Bio Ltd Multimers, tetramers & octamers
GB201906685D0 (en) 2019-05-13 2019-06-26 Ultrahuman Six Ltd Activatable protein constructs and uses thereof
EP3999528A4 (en) 2019-07-15 2023-10-25 Neogene Therapeutics B.V. METHOD FOR ISOLATION OF TCR GENES
DE102019121007A1 (de) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
EP4025598A1 (en) 2019-09-06 2022-07-13 Eli Lilly and Company Proteins comprising t-cell receptor constant domains
WO2021058807A1 (en) 2019-09-25 2021-04-01 Universität Stuttgart Trivalent binding molecules
BR112022004789A2 (pt) 2019-09-27 2022-06-21 Agenus Inc Proteínas heterodiméricas
JP2023502625A (ja) 2019-11-15 2023-01-25 グリットストーン バイオ インコーポレイテッド 共有新抗原を標的にする抗原結合タンパク質
WO2021099360A1 (en) 2019-11-18 2021-05-27 Medigene Immunotherapies Gmbh Prame tcr receptors and uses thereof
US20230051847A1 (en) 2019-12-17 2023-02-16 The Johns Hopkins University MANAbodies TARGETING TUMOR ANTIGENS AND METHODS OF USING
CN110964122B (zh) 2019-12-24 2022-04-15 南京北恒生物科技有限公司 T细胞受体融合蛋白及其用途
CA3171906A1 (en) 2020-03-16 2021-09-23 University Of Southern California Novel antigen binding domains and synthetic antigen receptors incorporating the same
US20230130925A1 (en) 2020-03-16 2023-04-27 University Of Southern California Methods to prevent, ameliorate and treat complications from viral infections
WO2021222576A1 (en) 2020-05-01 2021-11-04 A2 Biotherapeutics, Inc. Pag1 fusion proteins and methods of making and using same
AU2021289612A1 (en) 2020-06-10 2023-01-19 The University Of Melbourne HIV-1 antibodies
US20230272071A1 (en) 2020-07-27 2023-08-31 Michael S. Kuhns Multifunctional immunoglobulin-fold polypeptides from alternative translational initiation and termination
AU2021356681A1 (en) 2020-10-09 2023-05-18 Eureka Therapeutics Inc. Compositions targeting ndc80/mhc complexes and uses thereof
WO2022083668A1 (en) 2020-10-21 2022-04-28 Nanjing Legend Biotech Co., Ltd. Use of a chimeric co-stimulatory receptor for cell therapy
CA3167637A1 (en) 2020-12-21 2022-06-30 Eric Escobar-Cabrera Stabilized tcr constructs and methods of use
WO2022178367A2 (en) 2021-02-19 2022-08-25 University Of Southern California Single-chain and multi-chain synthetic antigen receptors for diverse immune cells

Also Published As

Publication number Publication date
TWI817302B (zh) 2023-10-01
SI3428194T1 (sl) 2021-12-31
US20190016803A1 (en) 2019-01-17
CA3069842A1 (en) 2019-01-17
CO2020001491A2 (es) 2020-02-28
CY1124091T1 (el) 2022-05-27
AU2018298884A1 (en) 2020-02-27
KR20200026994A (ko) 2020-03-11
WO2019012141A1 (en) 2019-01-17
BR112020000769A2 (pt) 2020-07-21
JP2024023385A (ja) 2024-02-21
ES2871146T3 (es) 2021-10-28
WO2019012138A1 (en) 2019-01-17
EP3985029A1 (en) 2022-04-20
CO2020001029A2 (es) 2020-02-18
EP3428194A1 (en) 2019-01-16
ZA202000842B (en) 2022-06-29
JP2020530762A (ja) 2020-10-29
BR112020000762A2 (pt) 2020-07-21
HUE057110T2 (hu) 2022-04-28
PL3428194T3 (pl) 2022-01-17
MA46299A (fr) 2019-07-31
HUE054568T2 (hu) 2021-09-28
TW202246330A (zh) 2022-12-01
PT3428194T (pt) 2021-11-18
US20220185888A1 (en) 2022-06-16
US11905328B2 (en) 2024-02-20
CN110914308A (zh) 2020-03-24
KR20200026995A (ko) 2020-03-11
TW201908340A (zh) 2019-03-01
US20190016801A1 (en) 2019-01-17
CY1124835T1 (el) 2022-11-25
JP2023103451A (ja) 2023-07-26
SG11202000025SA (en) 2020-02-27
MA46299B1 (fr) 2021-09-30
LT3428194T (lt) 2021-12-10
PT3652215T (pt) 2021-05-18
EP3652215B1 (en) 2021-02-17
US20190016802A1 (en) 2019-01-17
DK3428194T3 (da) 2021-11-15
SI3652215T1 (sl) 2021-08-31
DK3652215T3 (da) 2021-05-25
SG11202000027WA (en) 2020-02-27
US20230348598A1 (en) 2023-11-02
MD3428194T2 (ro) 2022-02-28
JP2019023184A (ja) 2019-02-14
CR20200014A (es) 2020-06-11
CA3069610A1 (en) 2019-01-17
RS62544B1 (sr) 2021-12-31
AU2018298881A1 (en) 2020-01-16
US20220195044A1 (en) 2022-06-23
PE20200615A1 (es) 2020-03-11
MX2020011744A (es) 2021-01-08
JP6784724B2 (ja) 2020-11-11
TWI762677B (zh) 2022-05-01
ES2898210T3 (es) 2022-03-04
EP3652215A1 (en) 2020-05-20
EP3428194B1 (en) 2021-08-18
CN110914307A (zh) 2020-03-24
PE20200614A1 (es) 2020-03-11
RS61817B1 (sr) 2021-06-30
LT3652215T (lt) 2021-05-25
US20190016804A1 (en) 2019-01-17
MD3652215T2 (ro) 2021-06-30
HRP20211744T1 (hr) 2022-02-04
PL3652215T3 (pl) 2021-08-02

Similar Documents

Publication Publication Date Title
CO2020001029A2 (es) Molécula de polipéptido con especificidad dual mejorada
GT201300233A (es) Receptores de celulas t similares a anticuerpos especificos para un peptido wt1 presentado por hla-a2
AR104718A1 (es) Receptores de antígenos quiméricos específicos de anti-gd3 para inmunoterapias contra el cáncer
CL2018000378A1 (es) Receptores de antígenos quiméricos basados en anticuerpos de dominio simple y métodos de uso de estos
UY36289A (es) ANTICUERPOS MONOCLONALES QUE ENLAZAN INMUNOESPECIFICAMENTE A CD123 y COMPOSICIONES QUE LOS CONTIENEN
AR110676A1 (es) Tratamiento del cáncer utilizando receptores de antígenos quiméricos
CL2018000461A1 (es) Anticuerpos biespecíficos con tetravalencia para un receptor de fnt coestimulador.
AU2018258045A1 (en) Chimeric antibody/T-cell receptor constructs and uses thereof
CL2020000452A1 (es) Anticuerpos de b7-h4 y métodos para usarlos.
BR112018014760A2 (pt) anticorpos anti-ror1, anticorpos biespecíficos para ror1 x cd3 e métodos de uso dos mesmos
MX2022011659A (es) Proteinas de union a antigeno que se unen a pd-l1.
CY1121743T1 (el) Μονοκλωνικα αντισωματα προς χρηση στη διαγνωση και θεραπεια απο καρκινους και αυτοανοση νοσο
CR20140585A (es) Proteinas de union a antigeno st2
UY35468A (es) Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
CY1121673T1 (el) Εξουδετερωση αντισωματων στις κυριες εξωτοξινες tcda και tcdb της λοιμωξης clostridium difficile
BR112021016984A2 (pt) Receptores de antígeno quimérico direcionados a dll3 e agentes de ligação
PE20210517A1 (es) Anticuerpos anti-hla-g y utilizacion de los mismos
CL2012002081A1 (es) Anticuerpo humanizado que se une a la cadena alfa del receptor de il-7 humano (cd127); proteina de enlace a antigeno que comprende una o mas regiones determinantes de complementariedad de dicho anticuerpo; molecula de acido nucleico que codifica una anticuerpo o proteina de enalce; vector de expresion, celula huesped recombinante; procedimiento para la produccion de una proteina de enlace a antigeno; procedimiento para tratar enfermedad autoinmune o inflamatoria.
AR112228A1 (es) Molécula de polipéptido con especificidad dual mejorada
MX2016005687A (es) Metodos para potenciar la terapia inmunosupresora mediante administracion multiple de polipeptido de union a tcr alfa beta.
MX2018016121A (es) Preparacion de anticuerpos monoclonales marcados con 212pb.
CO2018004930A2 (es) Moléculas de unión específicas para asct2
CO2020014343A2 (es) Anticuerpos específicos para cd3 y sus usos
CL2020001726A1 (es) Anticuerpos monoclonales y métodos para utilizar los mismos.
WO2014016702A3 (en) Humanized forms of monoclonal antibodies to human gnrh receptor